

Booth #1111, ASTRO 2026, Boston, MA

The Future of Radiotherapy is Here: Siemens Healthineers Launches Accela

- **The Accela¹ radiotherapy solution is engineered around NeoArc dynamic modulated arc therapy (DMAT)², a breakthrough technique combining speed and precision**
- **NeoArc makes single breath-hold stereotactic treatment possible and enables multi-site stereotactic body radiation therapy (SBRT) treatment in as little as 60 seconds**
- **With fast treatment delivery and planning, Accela makes complex treatment more practical and scalable for cancer centers**

Today Siemens Healthineers launched Accela, the first radiotherapy solution engineered around NeoArc, combining speed and precision for a broad range of cases while improving the scalability of complex treatments and reducing the time patients spend in radiotherapy treatment.

The Accela solution allows for single breath-hold stereotactic treatments and enables multi-site SBRT treatment in as little as 60 seconds, shortening patient time on the treatment table. The planning software's advanced AI and algorithms allow clinicians to balance the optimization of plan quality and delivery speed.

In addition, Accela brings unmatched linac functionality, with a large HyperSight cone-beam CT imaging panel, a newly designed multi-leaf collimator, high-speed gantry rotation at 2.5 RPM, dose rates up to 40 Gy/min, and a new eight-megavolt flattening filter-free energy setting.

"Accela is the kind of leap our field doesn't see often," said Dee Khuntia MD, chief medical officer at Varian, the Siemens Healthineers cancer-care business. "It's faster than previous systems, it's built on a fundamentally modern architecture, and it introduces a generational shift in treatment planning. But what excites me most is its potential to alter the biological response to radiotherapy. That's not incremental progress; it's a new chapter."

For healthcare systems facing a rising cancer burden, growing treatment complexity, and staffing constraints, Accela expands radiotherapy treatment options, enables faster, more precise workflows and an improved experience for patients and clinicians.

“Today’s announcement shows a level of innovation in radiotherapy only Siemens Healthineers can deliver,” said Arthur Kaindl, head of Varian. “It stands on a foundation that took decades to build: a global imaging business, our radiation-oncology installed base, mature AI and software, and long-term clinical relationships. We owe enormous gratitude to the thousands of colleagues whose work and ingenuity over the past eight years have brought us here.”

The development of Accela and NeoArc was informed through years of collaboration by Siemens Healthineers and an advisory group of leading cancer-research institutions: Mayo Clinic, Washington University School of Medicine Siteman Cancer Center, University Hospital Zurich, Seidman Cancer Center at University Hospitals Cleveland Medical Center, Maastricht - Maastricht Radiation Oncology Institute, Mass General Brigham Cancer Center, and Memorial Sloan Kettering Cancer Center (MSK). Their clinical input, research collaboration, and product evaluation have helped guide this innovation.

¹ 510(k) pending. Not available for sale in any market and no guarantee of commercialization or feature availability.

² DMAT is a new technique in radiation oncology using a faster gantry, multi-leaf collimator, and dose rate to create conformal treatment plans while improving treatment delivery times for patients.

Media contacts

Julie Gibson +1 917 929 5779; julie.gibson@siemens-healthineers.com

Ulrich Künzel +49 162 2433492; ulrich.kuenzel@siemens-healthineers.com

Visit the [Siemens Healthineers Press Center](#).

Subscribe to our [“Medtech matters” newsletter on LinkedIn](#).

Siemens Healthineers pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2025, which ended on September 30, 2025, Siemens Healthineers had approximately 74,000 employees worldwide and generated revenue of around €23.4 billion. Further information is available at [siemens-healthineers.com](https://www.siemens-healthineers.com).